Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2022 17:15 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
March 30, 2022 16:02 ET
|
Crinetics Pharmaceuticals, Inc.
– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 – – Advancing Phase 3 PATHFNDR Program Evaluating...
Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
March 30, 2022 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...
Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
March 21, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
March 14, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2022 17:20 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
March 01, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan
February 28, 2022 06:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and...
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
February 09, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2022 16:42 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...